Postdoctoral Researcher in PET-MRI Imaging: Join Dr. Bernard Lanz’s team at the CIBM MRI EPFL Animal Imaging and Technology Section for an exciting opportunity in the development of quantitative multimodal PET-MRI at ultrahigh field. This position involves innovative application in the follow-up of self-expand biomaterial expansion and tissue colonisation.
Postdoctoral Researcher in Preclinical Multimodal PET-MRI Imaging
Designation: Postdoctoral Researcher
Research Area: Preclinical Multimodal PET-MRI Imaging
Location: CIBM MRI EPFL, Lausanne, Switzerland
Eligibility/Qualification:
- PhD degree in (biomedical) physics, bioengineering, neuroscience, or similar field.
- Proficient in English, both verbal and written.
- Very good experimental skills for multimodal in vivo experiments.
- Experience in MRS, MRSI, Bruker scanner environment, and programming (Matlab, Python) preferred.
- Ready to work in a multidisciplinary research field.
Job Description: The selected candidate will participate in the development and optimization of simultaneous multimodal 9.4T MRI and FDG-PET measurements. Responsibilities include setup and optimization of imaging scanning protocols, image reconstruction, and development of FDG-PET injection protocols. Additionally, the candidate will collaborate on broader research scope projects and work closely with collaborators and technicians.
How to Apply: Interested candidates should send their CV and a motivation letter to bernard.lanz@epfl.ch. Applications will be considered until the position is filled, so early applications are encouraged.
Last Date for Apply: Applications will be considered until the position is filled.
About CIBM: The CIBM Center for Biomedical Imaging is a collaborative initiative involving EPFL, UNIL, UNIGE, HUG, and CHUV, supported by Fondation Leenaards and Fondation Louis-Jeantet. It brings together diverse and multidisciplinary groups focused on biomedical imaging.
About Volumina Medical: Volumina Medical is a startup spun off from EPFL, developing innovative biomaterials for regenerative medicine since 2018. It addresses unmet needs in reconstructive and plastic surgery and aesthetic medicine markets.
